

## DAFTAR PUSTAKA

- Aashish, Pandit, Tarun, Sachdeva, Pallavi, Bafna 2011, Drug-Induced Hepatotoxicity: A Review
- Annisa, R, Zarfiardy, A & Firdayenti 2015, *Perbandingan Kadar SGPT Pada Pasien Tuberkulosis Paru Sebelum dan Sesudah intensif di poliklinik paru RSUD Arifin Achmad Pekanbaru*, JOM FK, Vol.2 , No.2.
- Alexander, J, adami, Jorge, L & Cervantes 2015, *The microbiome at pulmonary alveolar niche and its role in mycobacterium tuberculosis infection*, Vol.95, No.6, hh.651-658.
- Ali, A, Belachew, T, Yami, A, Ayen, W 2013, Anti-Tuberculosis Drug Induced Hepatotoxicity among TB / HIV Co-Infected Patients at Jimma University Hospital, Ethiopia, Vol.8, No. 5, hh: 1–8.
- Almazroo, O, A, Miah M, K & Venkataramanan 2017, *Drug Metabolism in the Liver*. Clin Liver Dis, Vol.21, No.1, hh.1-20.
- Alomar M, J 2014, *Factors Affecting the Development of Adverse Drug Reactions*, King Saud University.
- Arbex, M, Varella, M, Siqueira, H, Mello, F 2010, *Antituberculosis drugs : drug interactions, adverse effects, and use in special situations*, Scielo Analytics, Vol. 36, No. 5, hh. 2.
- Aryaldy, Z , Rose, D, M 2010, *Gambaran Polifarmasi Pasien Geriatri Dibeberapa Poliklinik RSUP Dr. M. Djamil Padang*, Padang.
- Assob, J, C, N, Nde, P, F, Nsagha, D, S, Njunda, A, L, Ngum, N, M, Ngowe, M, N 2014, *AIDS & Clinical Incidence and Risk Factors of Anti-tuberculosis Drugs Induced Hepatotoxicity in HIV/AIDS Patients Attending the Limbe and Buea Regional Hospitals*, J AIDS Clin Res, Vol. 5, No.3.
- Babalik , A, Arda , H, Bakirci , N, Ağca , S, Oruç , K, Kiziltaş , Ş, *et al* 2012, *Management of and risk factors related to hepatotoxicity during tuberculosis treatment*, Tuberk Toraks, Vol. 60, No. 2, hh.136–44.
- Bayu, purnama 2014, *Hepatotoksitas Imbas Obat*. In: *Buku Ajar Ilmu Penyakit Dalam Jilid II*, Edisi VI. Jakarta: InternaPublishing.
- Bezu, H, Seifu, D, Yimer, G, Mebrhatu, T 2014, *Prevalence and Risk Factors of Adverse Drug Reactions Associated Multidrug Resistant Tuberculosis Treatments in Selected Treatment Centers in Addis Ababa Ethiopia*, J Tuberc Res, hh:144-54.
- Bourke, C, D, Berkley, J, A, Prendergast, A, J 2016, *Immune dysfunction as a cause and consequence of malnutrition*, Trends Immunol

Alya Andina Dasuki, 2021

**FAKTOR RESIKO KEJADIAN PENINGKATAN KADAR TRAMSAMINASE PADA PENGGUNAAN OBAT ANTI TUBERKULOSIS PASIEN TUBERKULOSIS PARU RST WIJAYAKUSUMA PURWOKERTO**

UPN Veteran Jakarta, Fakultas Kedokteran, Pendidikan Dokter

[www.upnvj.ac.id-[www.library.upnvj.ac.id](http://www.library.upnvj.ac.id)-www.repository.upnvj.ac.id]

- Brunton, LL, *et al*, Terjemahan E.Y. Sukandar, *et al* 2010, *Goodman & Gilman: Manual Farmakologi dan Terapi*, EGC, Jakarta.
- CDC, 2016, *Transmission and Pathogenesis of Tuberculosis*, <https://www.cdc.gov>
- Chalasan N, P, Hayashi P, H, Bonkovsky H, L, *et al* 2014, *ACG Clinical Guide: the diagnosis and management of idiosyncratic drug-induced liver injury*. *Am J Gastroenterol*, Vol.109, No.7, hh.950–966. doi: 10.1038/ajg.2014.131
- Common Terminology Criteria for Adverse Events (CTCAE) 2017, *Severity Grading in Hepatotoxicity*, Version 5.0.
- Clarasanti, I, CPW, Marthen, & JW, Bradley 2016, *Gambaran Enzim Transaminase pada Pasien Tuberkulosis Paru yang Diterapi dengan Obat Anti Tuberkulosis di RSUP Prof. Dr. R. D. Kandou*, Vol. 4, No.1.
- Dahlan, SM 2013, *Besar sampel dan cara pengambilan sampel*, Salemba Medika, Jakarta
- Depkes, RI 2014. *Riset Kesehatan Dasar*. Jakarta: Badan Penelitian dan pengembangan Kesehatan Kementerian Kesehatan RI.
- Departemen, Kesehatan 2016, *Pengendalian Penyakit dan Penyehatan Lingkungan, Pedoman nasional pengendalian tuberkulosis*, Jakarta.
- Edalo, Ahmed, S 2011, *Evaluation of The Effect of Antituberculous Drugs on the Liver and Renal functions' Tests in a Sudanese Cohort*.
- Eluwa G, I, Badru, T & Agu KA 2012, *Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria*, *BMC Clin Pharm*, Vol.12, No.7, doi: 10.1186/1472-6904-12-7.
- Garg, P, Garg, R, Prasad, R, Mishra, AK 2015, *A prospective study of ocular toxicity in patients receiving ethambutol as a part of directly observed treatment strategy therapy*. *J Lung*, India, Vol.32, No.1, hh. 16–9.
- Gede, Juliarta, Mulyantari, N, K & Yasa, I, W 2014, *Gambaran Hepatotoksisitas (Alt/Ast) Penggunaan Obat Anti Tuberkulosis Lini Pertama dalam Pengobatan Pasien Tuberkulosis Paru Rawat Inap di Rsup Sanglah Denpasar Tahun 2014*, Universitas Udayana, Bali.
- Gines, P, Kamath, PS, dan Arroyo, V 2011, *Chronic Liver Failure*, Humana Press, London, hh. 48-49.
- Grayson, ML 2010, *Kucers' The Use of Antibiotics 6th ed.*, London: Edward Arnold Ltd.

- Guyton A, C, John, E & Hall P, D 2012, *Textbook of Medical Physiology*, 12th ed. ,Elsevier, Philadelphia.
- Hachart ,B, Pamela 2016, *Tuberculosis Pathogenesis and Transmission, Oakland Country Michiga Health Division* , hh. 6,8,12,14,20-28
- Hayashi P, H & Fontana R, J 2014, *Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis*, Vol. 34, No. 2, hh.134–144. doi: 10.1055/s-0034-1375952.
- Heysell, S, K, *et al* 2011, *Plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob Agents Ch*, Vol. 55, No. 12, hh.5819–5825.
- Hoagland, D, T, Liu, J, Lee, R, B & Lee, R, E 2016, *New Agents for the Treatment of Drug- Resistant Mycobacterium tuberculosis, Advanced Drug Delivery Reviews*, No.102, hh.55–72.
- Hoofnagle J, H, Van, M, L, Kleiner D, E, Clark, J, M , Kowdley, K, V *et al* 2013, *VitaminE and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis*, *Aliment Pharmacol Ther*, Vol.38, No.2, hh.134-43
- Ingen, J, Van *et al* 2011, *Low-level rifampicin-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis*, Vol.15, No.7, hh.990–992.
- Jeong, I, Park, J, S, Co Y, J, Yoon, H, Song, J, Lee, C, T & Lee, J, H 2015, *Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci*, Vol.30, No.2, hh.167–172.
- Josephina, S, M & Walandow, D 2013, *Neuropati optik bilateral pasca terapi etambutol. J Biomedik*, Vol.5, No.1, hh.58–63.
- Kemenkes, RI 2015, *Pedoman Nasional Pengendalian Tuberkulosis*, hh. 20–37.
- Kementerian, Kesehatan, Indonesia, *Pedoman Nasional Pengendalian TB* 2014, Kementerian Kesehatan Indonesia, Jakarta.
- Kewalramani, M, S , Vaishnao, L, S, Jaiswal, K, M, Dudhgaonkar, S, Mahule, S, K, Raghute, L, B 2020, *Evaluation of Hepatotoxicity of Anti-Tuberculosis Regimens: A Prospective Study in Tribal Population of Central India*, Government Medical College, Gondia, Maharashtra, India.
- Khushboo, Ambreen, Rolee, Sharma, Kaleshwar, P, Singh & Sudhir Kumar 2014, *Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Review*, University of Lucknow, India.
- Kimmel, S,E, Leufkens, H, G & Rebbeck, T, R 2012, *Molecular epidemiology*. In B, L, Strom, S, E, Kimmel & S. Hennessy, eds. *Pharmacoepidemiology*, John Wiley & Sons, hh. 601–622.

Alya Andina Dasuki, 2021

**FAKTOR RESIKO KEJADIAN PENINGKATAN KADAR TRAMSAMINASE PADA PENGGUNAAN OBAT ANTI TUBERKULOSIS PASIEN TUBERKULOSIS PARU RST WIJAYAKUSUMA PURWOKERTO**

UPN Veteran Jakarta, Fakultas Kedokteran, Pendidikan Dokter

[[www.upnvj.ac.id](http://www.upnvj.ac.id)-[www.library.upnvj.ac.id](http://www.library.upnvj.ac.id)-[www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

- Krisnasari, 2010. *Nutrisi dan gizi buruk. Jurnal ilmiah kesehatan : Mandala of health*. Vol 4, no 1.
- Kowalak 2011, *Buku Ajar Patofisiologi*. Jakarta: EGC
- Latief, M, Dar W, R, Sofi N, Dar I, A, Kasana, B, Hussain, M et al 2017, Novel risk factors and early detection of antitubercular treatment induced liver injury : Looking beyond Thoracic Society Indian J Tuberc, 64(1):26
- Loho, I, K, A, Rambert, G, I & Wowor, M 2014, *Gambaran Kadar Ureum pada Pasien Penyakit Ginjal Kronik Stadium 5 Non Dialisis*. Jurnal e-Biomedik (eBm), 2(4) : 5
- Luthariana, Lies, Karjadi, Teguh H, Hasan, Irsan., Rumende, C, Martin 2017, *Faktor Risiko Terjadinya Hepatotoksisitas Imbas Obat Antituberkulosis pada Pasien HIV/AIDS*, Jurnal Penyakit dalam Indonesia Vol 4, No.1, hh. 23-28.
- McCommis K, S, Chen, Z, Fu, X, McDonald, W, G, Colca, J, R, Kletzien R, F, et al 2015, *Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling*. *Cell Metab*, Ed. 22, hh.682–694.
- Moore, K, L, Dalley, A, F, Agur, A, M, R, Moore, M, E 2013, *Anatomi berorientasi klinis*, Edisi ke-5, Erlangga, Jakarta.
- Munawarah, et al 2019, *Pengaruh Penggunaan Sediaan Fixed Dose Combination (Fdc) Dibandingkan Dengan Tablet Lepas Obat Anti-Tuberkulosis Terhadap Peningkatan Nilai Sgpt Dan Sgot Pada Pasien Tuberkulosis Di Balai Besar Kesehatan Paru Masyarakat Makassar*, Universitas Hasanuddin, Makassar.
- Naga, S 2012, *Ilmu Penyakit Dalam*, DIVA press, Jogjakarta.
- National Institute of Allergy and Infectious Diseases (NIAID), 2010, *Tuberculosis An Overview*. Chicago: U.S. Department of Health and Human Service.
- Ngouleun, W, Biapa, P, C, Pieme, A, C, Telefo P, B 2016, *Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS coinfecting patients under tuberculosis treatment*, *Int J Mycobacteriology*, Vol.5, No.4, hh :482-488.
- Padmapriyadarsini, Chandrasekaran, Natarajan, Saravanan, Ramalingam, Bethunaickan, Srikanth, Tripathy 2017, *Malnutrition: modulator of immune responses in tuberculosis*.

- Paramani, N 2013, *Hubungan dukungan pengawas minum obat (PMO) dengan kepatuhan berobat pasien Tuberkulosis Paru di Puskesmas Limboto Kabupaten Gorontalo*, Universitas Negeri Gorontalo.
- PDPI 2011, *Pedoman penatalaksanaan tb (konsensus tb)*, Perhimpunan Dokter Paru Indonesia, Jakarta.
- Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis.
- Peraturan Gubernur Jawa Tengah nomor 93 tahun 2018, *Rencana aksi daerah penanggulangan tuberkulosis provinsi jawa tengah tahun 2018*
- Pontoh, L, G, Polii, E. B. I. & Gosal, F 2016, *Gambaran bilirubin dan urobilinogen urin pada pasien tuberkulosis paru*, 4, pp. 0–5.
- Praditya, E, P 2012, *Profil Klinis Pasien Hepatitis Imbas OAT d RSU Siti Hajar Medan tahun 2012*, Medan.
- Purnomo, H 2016 , *Metabolisme Obat*, Pustaka pelajar , Yogyakarta
- Ramdhani, M, P, Alwinsyah, Keliat, E & Zuhriat 2011, *Pengenalan Kembali Obat Anti Tuberkulosa Pada Penderita Hepatitis Imbas Obat Akibat Obat Anti Tuberkulosa*, Jakarta.
- Ramappa, V, Aithal & Guruprasad, P 2013, *Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.*, Journal of Clinical and Experimental Hepatology, Vol.3, No.1, hh. 37-49.
- Resky, H, L, Willy, B, U & Widi R 2019, *Gambaran Kadar Enzim Transaminase pada Pasien Tuberkulosis yang Mendapat Terapi Obat Anti Tuberkulosis di Unit Pengobatan Penyakit Paru-Paru Provinsi Kalimantan*, Kalimantan.
- Robbins, Stanley, L, Kumar, Vinay, & Cotran, Ramzi, S 2011, *Buku Ajar Patologi*, Edisi 7, EGC, Jakarta.
- Ruhl, C, E & Everhart J, E 2010, *Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States*. *Gastroenterology*, Vol.138, No.4, hh.1346-56, 1356.e1-3.
- Sjihadat, Akhmed & Muthmainah, Siti 2013, *Analisis Interaksi Obat Pasien Rawat Inap di Rumah Sakit di Palu*. *Jurnal Farmasi Klinis Indonesia*, Vol.2, No. 4.
- Shang, P, Xia, Y, Liu, F, Wang, X, Yuan, Y, Hu, D, Tu, D, Chen, Y, Deng, P, Cheng, S, Zhou, L, Ma, Y, Zhu, L, Gao, W, Wang, H, Chen, D, Yang, L, He P, Wu, S, Tang, S, Lv, X, *et al* 2011, *Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China*, PLoS One, Vol.6, No.7, e21836.

Alya Andina Dasuki, 2021

**FAKTOR RESIKO KEJADIAN PENINGKATAN KADAR TRAMSAMINASE PADA PENGGUNAAN OBAT ANTI TUBERKULOSIS PASIEN TUBERKULOSIS PARU RST WIJAYAKUSUMA PURWOKERTO**

UPN Veteran Jakarta, Fakultas Kedokteran, Pendidikan Dokter

[[www.upnvj.ac.id](http://www.upnvj.ac.id)-[www.library.upnvj.ac.id](http://www.library.upnvj.ac.id)-[www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

- Shanmuganathan R and Shanmuganathan I, D 2015, *Clinical Manifestation and Risk Factors of Tuberculosis Infection in Malaysia: Case Study of a Community Clinic*, Malaysia.
- Snell, R, S 2012, *Anatomi Klinis Berdasarkan Sistem*, Dialih bahasakan oleh Sugarto L, EGC, Jakarta.
- Stefan, H, E & Kaufmann *et al* 2014, *Lancet Respir, Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review*, Elsevier
- Stevens, H, Ximenes, R, Dantas, O, Rodrigues, L 2014, *Risk factors for tuberculosis in older children and adolescents: a matched case-control study in Recife, Brazil. Emerging themes in epidemiology*, Vol.11, No. 1, hh.11-20.
- Sun, Q, Zhang, Q, Gu, J, Sun, W, Wang, P, Bai C 2016, *Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury : a prospective cohort study*, *Pharmacoepidemiology and Drug Safety*, 25(8):908-917.
- Suroyya, Gina, Dewi, Miranti, Kania, Dharmmika, Susanti 2016, *The Relationship Between Characteristics of Pulmonary TB Patients with Liver Dysfunction as a Side Effect of Anti Tuberculosis Drug in BBKPM Bandung in 2015-2016*, Bandung.
- Sylvia, A & Lorraine, M 2015, *Patofisiologi Edisi 6 : Konsep Klinis Proses- Proses Penyakit*, Vol. 2, EGC, Jakarta.
- Tampubolon, S, R, Ardana I, B, K & Sudira I, W 2014, *Aktivitas Alanin Aminotransferase dan Aspartat Aminotransferase Pada Mencit yang Diberikan Jamu Temulawak. Fakultas Kedokteran Hewan, Universitas Udayana : Bali*
- Teixeira, R, L, F, Lopes, P, N, Suffys & A, R, Santos 2013, *Tuberculosis Pharmacogenetics: State of The Art*. <http://dx.doi.org/10.5772/54984>.
- Thamaria, N 2017, *Bahan Ajar Gizi : Penilaian Status Gizi*, Pusat Pengembangan dan pemberdayaan Sumber Daya Manusia Kesehatan.
- Tsai JH, Ferrell LD, Tan V, Yeh MM, Sarkar M, Gill RM 2017. Aggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition. *Mod Pathol*
- Vedha P, J, S, Angel, P, Bhavya, E, Balaji, P & Murugan, M 2017, *Case study on Pulmonary Tuberculosis*, *International journal of Pharmcotherapy*, Vol.7, No,2 , hh. 54-55.

Vianna J, F, S, Bezerra, K, I, N, Oliveira, J, Albuquerque, E, L, Fulco, U, L 2019, *Binding energies of the drugs capreomycin and streptomycin in complex with tuberculosis bacterial ribosome subunits. Phys Chem Chem Phys*, 21;21(35):19192-19200

Vycke, Yunivita, Muhammad, Iqbal, Adi, Utomo, Suardi 2019, *Antituberculosis Drug-induced Hepatotoxicity in Pediatric Tuberculosis*.

